Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OH 2

Next Previous
X
Search
Drug Profile

OH 2

Alternative Names: BS-001; OH-2; OH2 injection; OH2 Oncolytic Viral Therapy; oHSV-2; Oncolytic type 2 Herpes Simplex virus; Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell); Recombinant Type II Herpes Simplex Virus Injection; rHSV2hGM-CSF

Latest Information Update: 22 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Binhui Biopharmaceutical
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Bladder cancer; Colorectal cancer
  • Phase I/II CNS cancer; Gastrointestinal cancer; Glioblastoma; Pancreatic cancer; Solid tumours
  • Phase I Liver cancer
  • Clinical Phase Unknown Head and neck cancer; Oesophageal cancer

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy and adverse events data from a phase I trial in Malignant melanoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 16 May 2024 Binhui Biopharmaceutical terminates a phase II trial in Colorectal cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in China (Intratumoural), due to strategy adjustment (NCT05648006)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top